NUS · Nu Skin Enterprises, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.61M | - | $364.21M | $386.14M | $364.49M | - | $430.14M | $439.08M | $417.31M | - |
| Cost of Revenue | $106.14M | - | $107.49M | $120.41M | $117.53M | - | $128.68M | $131.90M | $123.24M | - |
| Gross Profit | $214.46M | - | $256.72M | $265.73M | $246.96M | - | $301.46M | $307.18M | $294.06M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $98.54M | - | $104.82M | $106.72M | $113.20M | - | $115.62M | $117.92M | $124.57M | - |
| Total Operating Expenses | $210.44M | - | $235.08M | $234.95M | $256.86M | - | $283.23M | $432.73M | $285.24M | - |
| D&A | $12.34M | - | $12.09M | $13.05M | $14.21M | - | $17.32M | $17.60M | $18.44M | - |
| Operating Income | $4.03M | - | $21.64M | $30.78M | ($9.90M) | - | $18.23M | ($125.56M) | $8.82M | - |
| Interest Expense | $4.25M | - | $6.50M | $6.72M | $7.33M | - | $7.54M | $5.77M | $7.33M | - |
| Income Tax | $763.0K | - | ($1.08M) | $6.29M | $27.09M | - | $5.00M | ($13.39M) | $1.63M | - |
| Net Income | $1.84M | - | $17.08M | $21.12M | $107.52M | - | $8.30M | ($118.26M) | ($533.0K) | - |
| EPS - Basic | $0.04 | - | $0.35 | $0.43 | $2.16 | - | $0.17 | ($2.38) | ($0.01) | - |
| EPS - Diluted | $0.04 | - | $0.34 | $0.43 | $2.14 | - | $0.17 | ($2.38) | ($0.01) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $198.65M | $238.63M | $251.79M | $264.16M | $203.77M | $186.88M | $227.75M | $224.25M | $212.53M | $256.06M |
| Accounts Receivable | $45.01M | $39.54M | $48.89M | $59.70M | $56.58M | $50.78M | $68.81M | $71.55M | $67.04M | $72.88M |
| Inventory | $178.60M | $178.64M | $178.53M | $180.38M | $188.78M | $190.24M | $247.79M | $243.99M | $265.10M | $279.98M |
| Accounts Payable | $28.82M | $26.18M | $28.52M | $28.73M | $33.59M | $34.88M | $32.74M | $36.30M | $32.24M | $43.51M |
| Current Assets | $522.89M | $547.70M | $548.14M | $571.55M | $524.86M | $538.60M | $653.37M | $654.41M | $647.26M | $701.87M |
| Total Assets | $1.38B | $1.41B | $1.42B | $1.44B | $1.39B | $1.47B | $1.58B | $1.59B | $1.74B | $1.81B |
| Current Liabilities | $257.00M | $263.73M | $254.44M | $283.91M | $260.30M | $296.61M | $339.35M | $308.59M | $309.31M | $328.87M |
| Long-term Debt | $203.59M | $204.19M | $209.04M | $213.90M | $218.76M | $363.61M | $373.47M | $428.33M | $453.18M | $478.04M |
| Total Liabilities | $582.71M | $600.07M | $624.61M | $655.94M | $637.44M | $817.46M | $876.02M | $899.81M | $931.71M | $984.50M |
| Stockholders' Equity | $794.09M | $805.24M | $799.79M | $787.75M | $753.97M | $651.46M | $706.88M | $686.16M | $810.21M | $821.97M |
| Retained Earnings | $1.86B | $1.86B | $1.85B | $1.83B | $1.82B | $1.71B | $1.75B | $1.75B | $1.87B | $1.87B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.92M) | - | - | - | $389.0K | - | - | - | $3.32M | - |
| Investing Cash Flow | ($14.29M) | - | - | - | $181.54M | - | - | - | ($9.26M) | - |
| Financing Cash Flow | ($20.40M) | - | - | - | ($166.29M) | - | - | - | ($31.95M) | - |
| CapEx | $13.71M | - | - | - | $13.58M | - | - | - | $12.28M | - |
| Free Cash Flow | ($17.63M) | - | - | - | ($13.20M) | - | - | - | ($8.96M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.9% | - | 70.5% | 68.8% | 67.8% | - | 70.1% | 70.0% | 70.5% | - |
| Operating margin | 1.3% | - | 5.9% | 8.0% | -2.7% | - | 4.2% | -28.6% | 2.1% | - |
| EBITDA margin | 5.1% | - | 9.3% | 11.4% | 1.2% | - | 8.3% | -24.6% | 6.5% | - |
| Net margin | 0.6% | - | 4.7% | 5.5% | 29.5% | - | 1.9% | -26.9% | -0.1% | - |
| Free cash flow margin | -5.5% | - | - | - | -3.6% | - | - | - | -2.1% | - |
| FCF / Net income | -9.60 | - | - | - | -0.12 | - | - | - | 16.82 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 30.7% | - | 28.8% | 27.6% | 31.1% | - | 26.9% | 26.9% | 29.9% | - |
| Effective tax rate | 29.4% | - | -6.8% | 23.0% | 20.1% | - | 37.6% | - | 148.4% | - |
| Return on assets | 0.1% | - | 1.2% | 1.5% | 7.7% | - | 0.5% | -7.5% | -0.0% | - |
| Return on equity | 0.2% | - | 2.1% | 2.7% | 14.3% | - | 1.2% | -17.2% | -0.1% | - |
| Return on invested capital | 0.3% | - | 2.1% | 2.4% | -0.8% | - | 1.1% | -8.9% | 0.3% | - |
| Liquidity | ||||||||||
| Current ratio | 2.03 | 2.08 | 2.15 | 2.01 | 2.02 | 1.82 | 1.93 | 2.12 | 2.09 | 2.13 |
| Quick ratio | 1.34 | 1.40 | 1.45 | 1.38 | 1.29 | 1.17 | 1.20 | 1.33 | 1.24 | 1.28 |
| Cash ratio | 0.77 | 0.90 | 0.99 | 0.93 | 0.78 | 0.63 | 0.67 | 0.73 | 0.69 | 0.78 |
| Leverage | ||||||||||
| Debt / Equity | 0.26 | 0.25 | 0.26 | 0.27 | 0.29 | 0.56 | 0.53 | 0.62 | 0.56 | 0.58 |
| Debt / Assets | 0.15 | 0.15 | 0.15 | 0.15 | 0.16 | 0.25 | 0.24 | 0.27 | 0.26 | 0.26 |
| Debt / EBITDA | 12.44 | - | 6.20 | 4.88 | 50.84 | - | 10.50 | - | 16.63 | - |
| Interest coverage | 0.9x | - | 3.3x | 4.6x | -1.4x | - | 2.4x | -21.8x | 1.2x | - |
| Equity multiplier | 1.73 | 1.75 | 1.78 | 1.83 | 1.85 | 2.25 | 2.24 | 2.31 | 2.15 | 2.20 |
| Liabilities / Assets | 0.42 | 0.43 | 0.44 | 0.45 | 0.46 | 0.56 | 0.55 | 0.57 | 0.53 | 0.54 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | - | 0.26 | 0.27 | 0.26 | - | 0.27 | 0.28 | 0.24 | - |
| Inventory turnover | 0.59 | - | 0.60 | 0.67 | 0.62 | - | 0.52 | 0.54 | 0.46 | - |
| Days sales outstanding | 51d | - | 49d | 56d | 57d | - | 58d | 59d | 59d | - |
| Days inventory outstanding | 614d | - | 606d | 547d | 586d | - | 703d | 675d | 785d | - |
| Days payable outstanding | 99d | - | 97d | 87d | 104d | - | 93d | 100d | 95d | - |
| Cash conversion cycle | 566d | - | 558d | 516d | 539d | - | 668d | 634d | 748d | - |
| Valuation | ||||||||||
| P / E | 182.0x | - | 35.9x | 18.6x | 3.4x | - | 43.4x | - | - | - |
| P / B | 0.5x | - | 0.8x | 0.5x | 0.5x | - | 0.5x | 0.8x | 0.8x | - |
| P / S | 1.1x | - | 1.7x | 1.0x | 1.0x | - | 0.9x | 1.2x | 1.6x | - |
| EV / EBITDA | 22.3x | - | 16.9x | 7.9x | 88.4x | - | 14.4x | - | 34.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -12.0% | - | -15.3% | -12.1% | -12.7% | - | -13.8% | -12.2% | -13.3% | - |
| Revenue CAGR (3y) | -12.7% | - | -12.2% | -11.7% | -15.5% | - | -12.5% | -14.6% | -14.9% | - |
| Revenue CAGR (5y) | -13.9% | - | -12.3% | -8.8% | -6.8% | - | -6.1% | -6.8% | -7.7% | - |
| Gross profit growth (YoY) | -13.2% | - | -14.8% | -13.5% | -16.0% | - | 3.1% | -15.8% | -15.5% | - |
| Operating income growth (YoY) | - | - | 18.7% | - | - | - | - | - | -45.1% | - |
| Net income growth (YoY) | -98.3% | - | 105.7% | - | - | - | - | - | - | - |
| EPS growth (YoY) | -98.1% | - | 100.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | -44.2% | - | - | -13.7% | 41.2% | - | -44.0% | - | - | - |
| EPS CAGR (5y) | -46.5% | - | -20.6% | -11.9% | 42.8% | - | -26.5% | - | - | - |
| FCF growth (YoY) | -33.6% | - | - | - | -47.2% | - | - | - | 73.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 5.3% | 23.6% | 13.1% | 14.8% | -6.9% | -20.7% | -14.0% | -23.4% | -9.3% | -8.4% |
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing NU SKIN ENTERPRISES against the 5 most active filers in the same SIC group.
Dividends
$0.24/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.0600 |
| Feb 27, 2026 | $0.0600 |
| Nov 28, 2025 | $0.0600 |
| Aug 29, 2025 | $0.0600 |
| May 30, 2025 | $0.0600 |
| Feb 24, 2025 | $0.0600 |
| Nov 29, 2024 | $0.0600 |
| Aug 30, 2024 | $0.0600 |
| May 31, 2024 | $0.0600 |
| Feb 23, 2024 | $0.0600 |
| Nov 22, 2023 | $0.3900 |
| Aug 24, 2023 | $0.3900 |
| May 25, 2023 | $0.3900 |
| Feb 24, 2023 | $0.3900 |
| Nov 23, 2022 | $0.3850 |
| Aug 25, 2022 | $0.3850 |
| May 26, 2022 | $0.3850 |
| Feb 25, 2022 | $0.3850 |
| Nov 24, 2021 | $0.3800 |
| Aug 26, 2021 | $0.3800 |
| May 27, 2021 | $0.3800 |
| Feb 25, 2021 | $0.3800 |
| Nov 25, 2020 | $0.3750 |
| Aug 27, 2020 | $0.3750 |